FREE SHIPFree U.S. shipping on orders over $150Free U.S. shipping on orders over $150
Free U.S. shipping on orders over $150
Research-grade compound with certificate of analysis. Full analytical testing on every lot.
GHRP-6 stimulates growth hormone release, with cardioprotective and myoprotective benefits. Human Growth Hormone (HGH) Frag 176–191 is a synthetic 16-amino acid fragment of GH that isolates and enhances lipolysis without the growth-promoting and effects of full-length hGH. Together, GHRP-6 increases endogenous GH while HGH Frag 176–191 amplifies peripheral lipolysis, creating complementary effects.
GHRP-6 (Growth Hormone–Releasing Peptide-6) is a synthetic hexapeptide and member of the growth hormone secretagogue family [1]. It primarily functions as a ghrelin analog, binding to and activating the ghrelin receptor GHS-R1a and CD36 receptors. GHS-R1a is expressed in the hypothalamus, pituitary, hippocampus, along with the pancreas and liver. The CD36 is expressed in the cardiovascular system and macrophages, which may contribute to GHRP-6’s cardioprotective and anti-fibrotic effects observed in experimental models [1,2].
Originally developed as a growth hormone secretagogue, GHRP-6’s pharmacologic profile has expanded to include anabolic, cytoprotective, and potential cardiometabolic applications in preclinical research.
GHRP-6 works by stimulating the growth hormone/IGF-1 axis, increasing pituitary growth hormone release, and promoting downstream IGF-1 production and anabolic effects [1]. Since it’s the only GHRP that increases hunger and appetite, it may be helpful in conditions where increased caloric intake is beneficial [3]. Through interacting with CD36, which plays roles in fatty acid metabolism, inflammation, and tissue damage, GHRP-6 is thought to confer tissue-protective effects [1]. Importantly, GHRP-6 appears to act through mechanisms distinct from those of growth hormone–releasing factors [2].
Human Growth Hormone (HGH) Frag 176–191 is a modified peptide fragment derived from the C-terminal region of human growth hormone [4]. This 16-amino acid fragment corresponds to amino acids 176–191 of the full HGH molecule, modified with a tyrosine-to-phenylalanine substitution at position 191 to enhance stability and activity [4].
Unlike full-length growth hormone, HGH frag 176–191 does not replicate the complete growth-promoting effects of hGH [4]. Instead, it appears to isolate and amplify one specific functional region of the hormone, exerting more selective metabolic effects, including enhanced lipolysis, increased lipid utilization, and adipose tissue metabolism without strongly stimulating IGF-1-mediated growth pathways [4].
GHRP-6 and HGH frag 176–191 act at distinct points within the growth hormone signaling network. GHRP-6 works upstream through the ghrelin receptor, leading to downstream effects on metabolism, tissue repair, and lipolysis via physiologic GH pulses [5]. In contrast, HGH frag 176–191 exerts downstream effects, representing a small portion of the growth hormone molecule associated with fat metabolism [6]. HGH frag 176–191 appears to act more selectively on adipose tissue, with minimal activation of broader growth or IGF-1 pathways [6].
Mechanistically, this difference suggests the potential for complementary effects. By increasing natural pulsatile growth hormone release, GHRP-6 may enhance the body’s natural growth hormone rhythm, influencing substrate partitioning, promoting lipolysis, and supporting lean tissue maintenance [7].
Endogenous growth hormone’s metabolic actions include stimulating growth hormone–sensitive lipase, increasing fat breakdown, and reducing glucose uptake into adipocytes, shifting the body towards greater fat utilization. However, these effects depend heavily on overall energy balance and insulin status [3].
HGH frag 176–191 has demonstrated increased fat oxidation and reduced adipose accumulation in rodent models, without significantly stimulating IGF-1 or generalized tissue growth [6]. Because the fragment appears to emphasize fat-specific metabolic signaling, while GHRP-6 enhances upstream GH availability, their combined use has been hypothesized to align systemic hormone signaling with more targeted adipose effects.
The combined effect of GHRP-6 and HGH fragment 176–191 could create a stronger shift towards fat utilization while maintaining, or even concurrently building lean mass. Additionally, they engage different receptor pathways and are unlikely to compete directly, which makes complementary signaling biologically plausible [6, 7]. However, this is largely based on mechanistic reasoning rather than direct clinical studies examining the two together, and conclusions about combined effects are unknown. The 1:1 ratio of 5 mg of HGH frag 176–191 and 5 mg of GHRP-6 aligns with dosages studied in human metabolic trials evaluating fat metabolism.
References:
1 Berlanga-Acosta, J., Cibrian, D., Valiente-Mustelier, J., Suárez-Alba, J., García-Ojalvo, A., Falcón-Cama, V., et al. (2024) Growth hormone releasing peptide-6 (GHRP-6) prevents doxorubicin-induced myocardial and extra-myocardial damages by activating prosurvival mechanisms. Front. Pharmacol., Frontiers Media SA 15, 1402138
2 Wu, D., Chen, C., Zhang, J., Bowers, C. Y. and Clarke, I. J. (1996) The effects of GH-releasing peptide-6 (GHRP-6) and GHRP-2 on intracellular adenosine 3’,5'-monophosphate (cAMP) levels and GH secretion in ovine and rat somatotrophs. J. Endocrinol., Bioscientifica 148, 197–205
3 Granado, M., García-Cáceres, C., Frago, L. M., Argente, J. and Chowen, J. A. (2010) The positive effects of growth hormone-releasing peptide-6 on weight gain and fat mass accrual depend on the insulin/glucose status. Endocrinology, The Endocrine Society 151, 2008–2018
4 Habibullah, M. M., Mohan, S., Syed, N. K., Makeen, H. A., Jamal, Q. M. S., Alothaid, H., et al. (2022) Human growth hormone fragment 176-191 peptide enhances the toxicity of doxorubicin-loaded Chitosan nanoparticles against MCF-7 breast cancer cells. Drug Des. Devel. Ther., Informa UK Limited 16, 1963–1974
5 Fairhall, K. M., Mynett, A. and Robinson, I. C. (1995) Central effects of growth hormone-releasing hexapeptide (GHRP-6) on growth hormone release are inhibited by central somatostatin action. J. Endocrinol., Bioscientifica 144, 555–560
6 Heffernan, M. A., Thorburn, A. W., Fam, B., Summers, R., Conway-Campbell, B., Waters, M. J., et al. (2001) Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int. J. Obes. Relat. Metab. Disord., Springer Science and Business Media LLC 25, 1442–1449
7 Lei, T., Buchfelder, M., Fahlbusch, R. and Adams, E. F. (1995) Growth hormone releasing peptide (GHRP-6) stimulates phosphatidylinositol (PI) turnover in human pituitary somatotroph cells. J. Mol. Endocrinol., Bioscientifica 14, 135–138
Every lot undergoes five independent assays before release. Results are published in the lot-specific Certificate of Analysis.
Every lot undergoes our 4-panel testing protocol: HPLC purity analysis, ESI-MS identity confirmation, LAL endotoxin screening, and amino acid analysis (for peptides >15 residues). Full analytical data is published in the Certificate of Analysis for each lot.
Lyophilized peptides should be stored at -20°C or below for long-term stability. Once reconstituted, peptides should be stored at 2–8°C and used within a reasonable timeframe depending on the specific compound. Avoid repeated freeze-thaw cycles. Always store in a dry environment away from direct light.
Orders placed before noon PST, Monday–Saturday, ship the same day. We offer free standard shipping on orders over $150. All orders are shipped in insulated packaging with ice packs when necessary. Standard delivery typically takes 2–4 business days within the continental US.
No. All compounds sold by Genesis Peptides are strictly for in vitro and preclinical laboratory research purposes only. They are not approved for human consumption, therapeutic use, or diagnostic purposes. By purchasing, you confirm the products will be used solely for legitimate research applications.
A Certificate of Analysis (COA) is a document issued by our analytical laboratory that reports the results of all quality control tests performed on a specific lot of product. Each COA includes HPLC chromatograms, mass spectra, endotoxin results, and amino acid analysis where applicable. COAs are available in our COA Library for every lot we have shipped.
Yes. We offer volume pricing for universities, research institutions, and laboratories with recurring needs. Discounts begin at 10+ units and scale with volume. Contact our team for a custom quote tailored to your research requirements.
Research Use Only. All findings described above are derived from preclinical studies (animal models and in vitro experiments). GHRP-6 + Hgh Frag is not approved by the FDA for any diagnostic or therapeutic use in humans. Genesis Peptides makes no claims regarding human clinical efficacy. This product is sold exclusively for laboratory research.
FOR RESEARCH USE ONLY — Products are sold exclusively for in vitro and preclinical laboratory research. Not for human consumption or administration. Not intended for diagnostic or therapeutic use. These statements have not been evaluated by the FDA.
